Trade Zai Lab Limited - ZLAB CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.22 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Zai Lab Ltd ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 23.87 |
Open* | 24.84 |
1-Year Change* | -41.98% |
Day's Range* | 24.28 - 24.84 |
52 wk Range | 20.98-53.95 |
Average Volume (10 days) | 633.99K |
Average Volume (3 months) | 10.49M |
Market Cap | 2.70B |
P/E Ratio | -100.00K |
Shares Outstanding | 968.57M |
Revenue | 251.80M |
EPS | -4.09 |
Dividend (Yield %) | N/A |
Beta | 1.10 |
Next Earnings Date | Nov 7, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 22, 2023 | 24.33 | -0.35 | -1.42% | 24.68 | 24.84 | 24.18 |
Sep 21, 2023 | 23.87 | -0.44 | -1.81% | 24.31 | 24.40 | 23.68 |
Sep 20, 2023 | 25.27 | 0.41 | 1.65% | 24.86 | 25.73 | 24.86 |
Sep 19, 2023 | 25.24 | -0.06 | -0.24% | 25.30 | 25.34 | 24.04 |
Sep 18, 2023 | 25.70 | -0.28 | -1.08% | 25.98 | 27.71 | 25.56 |
Sep 15, 2023 | 25.69 | 0.42 | 1.66% | 25.27 | 25.92 | 24.96 |
Sep 14, 2023 | 25.51 | 0.30 | 1.19% | 25.21 | 26.42 | 25.21 |
Sep 13, 2023 | 24.99 | -1.49 | -5.63% | 26.48 | 26.48 | 24.92 |
Sep 12, 2023 | 26.42 | 1.07 | 4.22% | 25.35 | 26.43 | 25.35 |
Sep 11, 2023 | 26.38 | -0.44 | -1.64% | 26.82 | 27.41 | 25.99 |
Sep 8, 2023 | 26.32 | -0.51 | -1.90% | 26.83 | 26.98 | 25.79 |
Sep 7, 2023 | 27.24 | 0.29 | 1.08% | 26.95 | 27.84 | 26.26 |
Sep 6, 2023 | 28.12 | 0.25 | 0.90% | 27.87 | 28.17 | 27.28 |
Sep 5, 2023 | 28.56 | -0.06 | -0.21% | 28.62 | 28.77 | 27.93 |
Sep 1, 2023 | 26.00 | 0.35 | 1.36% | 25.65 | 26.38 | 25.49 |
Aug 31, 2023 | 25.36 | -0.63 | -2.42% | 25.99 | 26.69 | 25.23 |
Aug 30, 2023 | 26.41 | 2.31 | 9.59% | 24.10 | 26.71 | 24.10 |
Aug 29, 2023 | 23.74 | 0.96 | 4.21% | 22.78 | 23.87 | 22.39 |
Aug 28, 2023 | 22.72 | -0.63 | -2.70% | 23.35 | 23.63 | 22.39 |
Aug 25, 2023 | 23.94 | -0.14 | -0.58% | 24.08 | 24.08 | 23.35 |
Zai Lab Limited Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 215.04 | 144.312 | 48.958 | 12.985 | 0.12945 |
Total Operating Expense | 619.397 | 844.376 | 350.759 | 216.181 | 141.898 |
Selling/General/Admin. Expenses, Total | 258.971 | 218.831 | 111.312 | 70.211 | 21.5759 |
Research & Development | 286.408 | 573.306 | 222.711 | 142.221 | 120.278 |
Operating Income | -404.357 | -700.064 | -301.801 | -203.196 | -141.768 |
Interest Income (Expense), Net Non-Operating | -41.821 | 2.19 | 4.939 | 7.939 | 3.22096 |
Other, Net | 3.113 | -5.54 | 29.076 | 0.938 | 0.05878 |
Net Income Before Taxes | -443.065 | -703.414 | -267.786 | -194.319 | -138.488 |
Net Income After Taxes | -443.065 | -703.414 | -267.786 | -194.319 | -138.488 |
Net Income Before Extra. Items | -443.286 | -704.471 | -268.905 | -195.071 | -139.075 |
Net Income | -443.286 | -704.471 | -268.905 | -195.071 | -139.075 |
Income Available to Common Excl. Extra. Items | -443.286 | -704.471 | -268.905 | -195.071 | -139.075 |
Income Available to Common Incl. Extra. Items | -443.286 | -704.471 | -268.905 | -195.071 | -139.075 |
Dilution Adjustment | |||||
Diluted Net Income | -443.286 | -704.471 | -268.905 | -195.071 | -139.075 |
Diluted Weighted Average Shares | 958.067 | 929.921 | 77.6677 | 64.3695 | 52.6098 |
Diluted EPS Excluding Extraordinary Items | -0.46269 | -0.75756 | -3.46225 | -3.03049 | -2.64352 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -0.46269 | -0.75756 | -3.46225 | -3.03049 | -2.64352 |
Equity In Affiliates | -0.221 | -1.057 | -1.119 | -0.752 | -0.58655 |
Revenue | 215.04 | 144.312 | 48.958 | 12.985 | 0.12945 |
Cost of Revenue, Total | 74.018 | 52.239 | 16.736 | 3.749 | 0.04359 |
Gross Profit | 141.022 | 92.073 | 32.222 | 9.236 | 0.08586 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 68.864 | 62.797 | 62.601 | 57.54 | 48.176 |
Revenue | 68.864 | 62.797 | 62.601 | 57.54 | 48.176 |
Cost of Revenue, Total | 23.763 | 21.337 | 20.924 | 20.044 | 17.407 |
Gross Profit | 45.101 | 41.46 | 41.677 | 37.496 | 30.769 |
Total Operating Expense | 158.365 | 132.319 | 159.894 | 186.123 | 146.892 |
Selling/General/Admin. Expenses, Total | 67.92 | 62.51 | 72.024 | 66.555 | 63.401 |
Research & Development | 76.682 | 48.472 | 66.946 | 99.524 | 66.084 |
Operating Income | -89.501 | -69.522 | -97.293 | -128.583 | -98.716 |
Interest Income (Expense), Net Non-Operating | -29.989 | 19.144 | -47.056 | 3.872 | 1.175 |
Other, Net | -1.405 | 1.234 | 82.58 | -36.479 | -40.392 |
Net Income Before Taxes | -120.895 | -49.144 | -61.769 | -161.19 | -137.933 |
Net Income After Taxes | -120.895 | -49.144 | -61.769 | -161.19 | -137.933 |
Equity In Affiliates | 0 | 0 | 0 | 0 | 0 |
Net Income Before Extra. Items | -120.895 | -49.144 | -61.769 | -161.19 | -137.933 |
Net Income | -120.895 | -49.144 | -61.769 | -161.19 | -137.933 |
Income Available to Common Excl. Extra. Items | -120.895 | -49.144 | -61.769 | -161.19 | -137.933 |
Income Available to Common Incl. Extra. Items | -120.895 | -49.144 | -61.769 | -161.19 | -137.933 |
Diluted Net Income | -120.895 | -49.144 | -61.769 | -161.19 | -137.933 |
Diluted Weighted Average Shares | 964.817 | 961.445 | 959.949 | 959.086 | 957.685 |
Diluted EPS Excluding Extraordinary Items | -0.1253 | -0.05111 | -0.06435 | -0.16807 | -0.14403 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.13567 | -0.05111 | -0.06435 | -0.16807 | -0.14403 |
Unusual Expense (Income) | -10 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1124.34 | 1500.88 | 1216.04 | 292.464 | 269.144 |
Cash and Short Term Investments | 1008.47 | 1409.1 | 1186.79 | 275.932 | 263.302 |
Cash | 1007.42 | 663.472 | 441.283 | 75.111 | 36.778 |
Cash & Equivalents | 1.047 | 300.628 | 0.833 | 0.821 | 26.1736 |
Prepaid Expenses | 35.674 | 18.021 | 10.935 | 6.736 | 5.74926 |
Total Assets | 1220.14 | 1609.96 | 1297.64 | 355.153 | 301.987 |
Property/Plant/Equipment, Total - Net | 77.375 | 57.291 | 46.863 | 36.424 | 20.4945 |
Property/Plant/Equipment, Total - Gross | 99.439 | 73.716 | 57.115 | 41.885 | 22.7024 |
Accumulated Depreciation, Total | -22.064 | -16.425 | -10.252 | -5.461 | -2.20792 |
Intangibles, Net | 8.403 | 9.659 | 9.44 | 8.803 | 0.32157 |
Long Term Investments | 6.431 | 15.605 | 1.279 | 2.398 | 3.14986 |
Note Receivable - Long Term | 0 | 23.858 | 22.141 | 13.737 | 8.04426 |
Other Long Term Assets, Total | 3.595 | 2.662 | 1.879 | 1.327 | 0.83259 |
Total Current Liabilities | 139.842 | 192.901 | 98.043 | 46.635 | 48.8415 |
Accounts Payable | 65.974 | 126.163 | 62.641 | 22.66 | 37.432 |
Accrued Expenses | 38.739 | 31.612 | 18.9 | 13.941 | 3.69917 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 6.45 | 3.64262 |
Other Current Liabilities, Total | 35.129 | 35.126 | 16.502 | 3.584 | 4.06767 |
Total Liabilities | 174.545 | 230 | 128.293 | 60.493 | 50.9054 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 34.703 | 37.099 | 30.25 | 13.858 | 2.06394 |
Total Equity | 1045.59 | 1379.96 | 1169.34 | 294.66 | 251.082 |
Redeemable Preferred Stock | |||||
Common Stock | 0.006 | 0.006 | 0.005 | 0.004 | 0.00348 |
Additional Paid-In Capital | 2893.12 | 2825.95 | 1897.47 | 734.734 | 498.043 |
Retained Earnings (Accumulated Deficit) | -1861.36 | -1418.07 | -713.603 | -444.698 | -249.627 |
Other Equity, Total | 25.685 | -23.645 | -14.524 | 4.62 | 2.66173 |
Total Liabilities & Shareholders’ Equity | 1220.14 | 1609.96 | 1297.64 | 355.153 | 301.987 |
Total Common Shares Outstanding | 960.22 | 95.4981 | 87.811 | 68.2373 | 49.9126 |
Short Term Investments | 0 | 445 | 744.676 | 200 | 200.35 |
Total Receivables, Net | 48.571 | 54.809 | 5.165 | 3.791 | 0.08971 |
Accounts Receivable - Trade, Net | 39.963 | 47.474 | 5.165 | 3.791 | 0.08971 |
Total Inventory | 31.621 | 18.951 | 13.144 | 6.005 | 0.00382 |
Treasury Stock - Common | -11.856 | -4.279 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 1072.3 | 1124.34 | 1209.83 | 1335.65 | 1393.25 |
Cash and Short Term Investments | 930.394 | 1008.47 | 1119.48 | 1256.09 | 1312.23 |
Cash | 878.786 | 1007.42 | 818.407 | 381.225 | 547.259 |
Cash & Equivalents | 1.058 | 1.047 | 301.069 | 299.595 | 299.698 |
Short Term Investments | 50.55 | 0 | 0 | 575.274 | 465.274 |
Total Receivables, Net | 60.727 | 48.571 | 39.067 | 38.241 | 44.242 |
Accounts Receivable - Trade, Net | 43.346 | 39.963 | 27.736 | 27.054 | 33.394 |
Total Inventory | 38.405 | 31.621 | 29.131 | 23.339 | 20.288 |
Prepaid Expenses | 42.772 | 35.674 | 22.157 | 17.973 | 16.49 |
Total Assets | 1170.07 | 1220.14 | 1298.51 | 1418.78 | 1500.92 |
Property/Plant/Equipment, Total - Net | 78.457 | 77.375 | 70.797 | 65.015 | 62.213 |
Property/Plant/Equipment, Total - Gross | 102.936 | 99.439 | 91.11 | 84.148 | 80.461 |
Accumulated Depreciation, Total | -24.479 | -22.064 | -20.313 | -19.133 | -18.248 |
Intangibles, Net | 8.399 | 8.403 | 8.364 | 8.959 | 9.519 |
Long Term Investments | 6.872 | 6.431 | 3.316 | 2.827 | 8.444 |
Note Receivable - Long Term | 0 | 0.006 | 0.037 | 20.766 | |
Other Long Term Assets, Total | 4.048 | 3.595 | 6.2 | 6.292 | 6.722 |
Total Current Liabilities | 124.56 | 139.842 | 155.548 | 168.877 | 154.912 |
Accounts Payable | 66.361 | 65.974 | 90.112 | 108.443 | 98.161 |
Accrued Expenses | 18.79 | 38.739 | 32.188 | 25.8 | 23.113 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 39.409 | 35.129 | 33.248 | 34.634 | 33.638 |
Total Liabilities | 168.832 | 174.545 | 192.645 | 206.612 | 192.907 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 44.272 | 34.703 | 37.097 | 37.735 | 37.995 |
Total Equity | 1001.24 | 1045.59 | 1105.87 | 1212.17 | 1308.01 |
Common Stock | 0.006 | 0.006 | 0.006 | 0.006 | 0.006 |
Additional Paid-In Capital | 2911.45 | 2893.12 | 2877.36 | 2857.2 | 2838.66 |
Retained Earnings (Accumulated Deficit) | -1910.5 | -1861.36 | -1799.59 | -1638.4 | -1500.47 |
Other Equity, Total | 17.272 | 25.685 | 39.549 | 4.487 | -25.838 |
Total Liabilities & Shareholders’ Equity | 1170.07 | 1220.14 | 1298.51 | 1418.78 | 1500.92 |
Total Common Shares Outstanding | 963.689 | 960.22 | 959.725 | 958.495 | 956.637 |
Treasury Stock - Common | -16.986 | -11.856 | -11.456 | -11.129 | -4.347 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -443.286 | -704.471 | -268.905 | -195.071 | -139.075 |
Cash From Operating Activities | -367.642 | -549.231 | -216.055 | -191.011 | -97.538 |
Cash From Operating Activities | 8.227 | 6.487 | 4.64 | 3.766 | 1.63438 |
Amortization | 0.0154 | ||||
Non-Cash Items | 133.187 | 124.275 | 29.935 | 23.577 | 12.5049 |
Changes in Working Capital | -65.77 | 24.478 | 18.275 | -23.283 | 27.3822 |
Cash From Investing Activities | 420.016 | 249.957 | -554.83 | -14.892 | -212.554 |
Capital Expenditures | -24.984 | -18.948 | -10.669 | -15.242 | -10.1178 |
Other Investing Cash Flow Items, Total | 445 | 268.905 | -544.161 | 0.35 | -202.436 |
Cash From Financing Activities | -1.73 | 820.202 | 1132.44 | 219.302 | 144.147 |
Issuance (Retirement) of Stock, Net | 5.87 | 824.455 | 1138.97 | 216.401 | 140.504 |
Foreign Exchange Effects | -6.274 | 1.116 | 4.862 | 0.091 | -0.76342 |
Net Change in Cash | 44.37 | 522.044 | 366.417 | 13.49 | -166.709 |
Cash Interest Paid | 0 | 0 | 0.189 | 0.288 | 0.0358 |
Issuance (Retirement) of Debt, Net | 0 | 0 | -6.527 | 2.901 | 3.64262 |
Financing Cash Flow Items | -7.6 | -4.253 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -49.144 | -443.286 | -381.517 | -220.327 | -82.394 |
Cash From Operating Activities | -69.287 | -367.642 | -258.35 | -132.027 | -87.127 |
Cash From Operating Activities | 2.657 | 8.227 | 6.1 | 3.874 | 2.013 |
Non-Cash Items | 9.255 | 133.187 | 134.847 | 41.836 | 20.867 |
Cash Interest Paid | 0 | ||||
Changes in Working Capital | -32.055 | -65.77 | -17.78 | 42.59 | -27.613 |
Cash From Investing Activities | -53.954 | 420.016 | 424.389 | -143.869 | -30.144 |
Capital Expenditures | -3.516 | -24.984 | -20.611 | -13.595 | -9.895 |
Other Investing Cash Flow Items, Total | -50.438 | 445 | 445 | -130.274 | -20.249 |
Cash From Financing Activities | -3.886 | -1.73 | -1.531 | -2.24 | 0.258 |
Issuance (Retirement) of Stock, Net | 1.197 | 5.87 | 5.64 | 4.619 | 0.297 |
Issuance (Retirement) of Debt, Net | 0 | ||||
Foreign Exchange Effects | -1.299 | -6.274 | -9.132 | -5.144 | -0.13 |
Net Change in Cash | -128.426 | 44.37 | 155.376 | -283.28 | -117.143 |
Financing Cash Flow Items | -5.083 | -7.6 | -7.171 | -6.859 | -0.039 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Capital World Investors | Investment Advisor | 5.2849 | 5223568 | 557699 | 2023-06-30 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 3.7301 | 3686754 | 1815712 | 2023-06-30 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 3.5809 | 3539301 | -1161245 | 2023-06-30 | LOW |
Viking Global Investors LP | Investment Advisor/Hedge Fund | 2.6603 | 2629445 | 298200 | 2023-06-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.6526 | 2621802 | 215729 | 2023-06-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.0997 | 2075352 | 760307 | 2023-06-30 | LOW |
Segantii Capital Management Limited | Hedge Fund | 1.8166 | 1795479 | -482796 | 2023-06-30 | HIGH |
Baron Capital Management, Inc. | Investment Advisor/Hedge Fund | 1.5298 | 1512061 | 86847 | 2023-06-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.5134 | 1495869 | -1175601 | 2023-06-30 | LOW |
Genesis Investment Management, LLP | Investment Advisor/Hedge Fund | 1.3681 | 1352222 | -217542 | 2023-06-30 | LOW |
Qiming Venture Partners | Venture Capital | 1.2829 | 1268000 | -6654932 | 2022-12-31 | LOW |
Rock Springs Capital Management LP | Hedge Fund | 1.2368 | 1222423 | 162723 | 2023-06-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0804 | 1067883 | 433972 | 2022-12-31 | LOW |
Du (Samantha Ying) | Individual Investor | 1.0145 | 1002701 | 1002701 | 2023-04-17 | |
Capital International Investors | Investment Advisor | 0.9782 | 966853 | 250155 | 2023-06-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.9456 | 934602 | 161982 | 2023-06-30 | LOW |
Paradigm BioCapital Advisors LP | Investment Advisor | 0.8755 | 865297 | 84739 | 2023-06-30 | LOW |
ClearBridge Investments, LLC | Investment Advisor/Hedge Fund | 0.8208 | 811314 | 15101 | 2023-06-30 | LOW |
SC China Holding Ltd | Investment Advisor | 0.7028 | 694634 | 0 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.6776 | 669739 | -616150 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Zai Lab Limited Company profile
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.Industry: | Biopharmaceuticals |
4560 Jinke Road
Bldg. 1, 4/F
SHANGHAI
SHANGHAI 201210
CN
Income Statement
- Annual
- Quarterly
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com